NSG 508 Week 3 Discussion

Student Name

University of Phoenix

NSG/508 Theoretical Foundations of Advanced Nursing Practice

Prof. Name:

Date

Mild Persistent Asthma in an Adolescent:

Mild persistent asthma in adolescents is best managed with a combination of daily controller therapy, quick-relief medication, regular monitoring, and trigger avoidance. For a 15-year-old patient with exercise-induced shortness of breath, nighttime coughing, wheezing, and allergic symptoms, current clinical guidelines recommend initiating a low-dose inhaled corticosteroid (ICS) alongside a short-acting beta₂-agonist (SABA) for symptom relief. Effective asthma management also requires patient education, adherence to treatment, and environmental control measures to improve long-term outcomes and quality of life.

Patient Case Overview

M. L. is a 15-year-old Hispanic female who plays soccer for her school team and presents with symptoms consistent with mild persistent asthma. She experiences shortness of breath during exercise, frequent dry cough, nighttime awakenings due to coughing at least four times per week, wheezing, and symptoms of allergic rhinitis, including a runny nose and itchy eyes. Physical examination reveals pale, swollen nasal mucosa, bilateral expiratory wheezing, a respiratory rate of 22 breaths per minute, and a peak expiratory flow (PEF) of 400. Her cardiovascular examination is normal, and there is no cyanosis.

Her family history is significant for seasonal allergies in both parents and asthma in her mother, increasing her risk for allergic asthma.

Pharmacotherapy Goals for Mild Persistent Asthma

The primary goals of asthma pharmacotherapy are to achieve and maintain symptom control while minimizing future risks such as exacerbations and declining lung function. Treatment should also allow adolescents to participate fully in physical activities without limitations.

Key treatment goals include:

Prevent daytime and nighttime asthma symptoms.
Eliminate nighttime awakenings caused by coughing.
Improve exercise tolerance and athletic performance.
Reduce airway inflammation.
Prevent asthma exacerbations and emergency care visits.
Minimize the need for rescue inhaler use.
Maintain normal pulmonary function.
Control associated allergic rhinitis symptoms.
Improve overall quality of life while minimizing medication side effects.

Recommended Drug Therapy

Low-Dose Inhaled Corticosteroid (ICS)

A low-dose inhaled corticosteroid is the preferred first-line controller medication for adolescents with mild persistent asthma. Inhaled corticosteroids reduce chronic airway inflammation, decrease airway hyperresponsiveness, improve lung function, and significantly lower the risk of asthma exacerbations.

Common treatment options include:

Budesonide
Fluticasone
Beclomethasone

Consistent daily use is essential because inhaled corticosteroids target airway inflammation rather than providing immediate symptom relief.

Short-Acting Beta₂-Agonist (SABA)

A rescue inhaler containing a short-acting beta₂-agonist should be prescribed for rapid relief of acute bronchospasm.

Common examples include:

Albuterol (Ventolin)
Albuterol (ProAir)
Albuterol (Proventil)

The rescue inhaler should also be used before exercise if exercise-induced bronchospasm occurs.

Management of Allergic Rhinitis

Because M. L. demonstrates symptoms of allergic rhinitis, treatment of allergies is important for optimal asthma control. Second-generation antihistamines may reduce nasal symptoms without causing significant sedation.

Examples include:

Cetirizine (Zyrtec)
Loratadine (Claritin)

If symptoms persist, an intranasal corticosteroid may provide greater symptom relief. Allergy testing may also help identify environmental allergens contributing to asthma exacerbations. Patients with multiple positive allergy tests often experience more severe asthma, and allergen immunotherapy may be considered for appropriate candidates.

Monitoring the Success of Therapy

Asthma management requires regular follow-up to determine whether treatment goals are being achieved and whether therapy should be adjusted.

Patients should typically be reassessed within 1 to 3 months after initiating therapy and every 3 to 12 months thereafter, depending on symptom control.

Important monitoring parameters include:

Frequency of daytime asthma symptoms.
Number of nighttime awakenings.
Use of rescue inhaler.
Exercise tolerance.
Peak expiratory flow (PEF) or spirometry results.
Frequency of asthma exacerbations.
School attendance and physical activity participation.
Medication adherence.
Correct inhaler technique.
Adverse medication effects.

If asthma remains well controlled for at least three months, treatment may be stepped down under clinical supervision. Conversely, persistent symptoms may require stepping up therapy after confirming medication adherence, inhaler technique, and trigger avoidance.

Age-Appropriate Health Promotion Strategies

Asthma education is a critical component of long-term disease management, particularly during adolescence when independence and self-management skills are developing.

Asthma Self-Management Education

M. L. should receive education on:

Correct inhaler technique.
Daily adherence to controller medication.
Appropriate use of rescue medication.
Recognizing early warning signs of worsening asthma.
Following a personalized asthma action plan.

Environmental Trigger Control

Reducing allergen exposure can significantly improve asthma control.

Recommended environmental measures include:

Reducing dust mite exposure by washing bedding weekly in hot water.
Minimizing exposure to pet dander when applicable.
Preventing mold growth in the home.
Controlling cockroach exposure.
Monitoring local pollen counts before outdoor activities.
Avoiding tobacco smoke exposure.
Limiting exposure to perfumes, scented candles, aerosol sprays, and strong cleaning products.

Exercise Recommendations

Regular physical activity should be encouraged because well-controlled asthma should not prevent participation in sports. If exercise consistently triggers symptoms, using a rescue inhaler before activity may help prevent exercise-induced bronchospasm.

Psychosocial Support

Adolescents may experience embarrassment or anxiety about using inhalers at school or during sports. Healthcare providers should encourage open communication regarding medication adherence and assess for anxiety, depression, or social concerns that could interfere with treatment.

Clinical Takeaways

Mild persistent asthma in adolescents is effectively managed with daily low-dose inhaled corticosteroids, a rescue bronchodilator, and comprehensive patient education. Treating associated allergic rhinitis, monitoring symptom control, and minimizing environmental triggers significantly improve asthma outcomes. Regular follow-up allows healthcare providers to adjust therapy using a stepwise approach while helping adolescents maintain normal daily activities and athletic participation.

What is the first-line treatment for mild persistent asthma in adolescents?

A daily low-dose inhaled corticosteroid combined with a short-acting beta₂-agonist for quick symptom relief is the preferred first-line treatment according to current asthma management guidelines.

Why should allergic rhinitis be treated in patients with asthma?

Allergic rhinitis and asthma frequently coexist. Controlling nasal allergies reduces airway inflammation, improves asthma control, and decreases the frequency of asthma exacerbations.

How often should asthma therapy be reassessed?

Most clinical guidelines recommend reassessing patients within 1 to 3 months after initiating treatment. Once asthma is stable, follow-up every 3 to 12 months is generally appropriate.

Can adolescents with asthma participate in sports?

Yes. With proper asthma control, medication adherence, and pre-exercise management when needed, adolescents can safely participate in sports and other physical activities.

What should patients monitor at home?

Patients should monitor symptom frequency, nighttime awakenings, rescue inhaler use, exercise tolerance, peak flow measurements when recommended, and exposure to known asthma triggers.

Summary

Mild persistent asthma in adolescents is primarily managed with daily low-dose inhaled corticosteroids and a short-acting beta₂-agonist for symptom relief. Treatment aims to control symptoms, prevent exacerbations, improve exercise tolerance, and maintain normal lung function. Management should also include treatment of allergic rhinitis, patient education, trigger avoidance, regular assessment of asthma control, and stepwise adjustment of therapy based on clinical response.

References

Arcangelo, V. P., Peterson, A. M., Wilbur, V., & Reinhold, J. A. (2017). Pharmacotherapeutics for Advanced Practice: A Practical Approach (4th ed.). Wolters Kluwer.

Global Initiative for Asthma. (2024). Global Strategy for Asthma Management and Prevention. https://ginasthma.org

National Asthma Education and Prevention Program. (2020). 2020 Focused Updates to the Asthma Management Guidelines. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov